Maxim Group Assumes Momenta Pharmaceuticals (MNTA) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Momenta Phama's (MNTA) Necuparanib Receives Orphan Drug Designation from FDA
June 5, 2014 8:05 AM EDTMomenta Phama (NASDAQ: MNTA) announced that its novel oncology candidate, necuparanib (formerly M402), has received Orphan Drug Designation from the FDA for the treatment of pancreatic cancer.
"We are pleased to receive Orphan Drug Designation for... More
